ArticleLa Radiologia medica2023
Stereotactic boost on residual disease after external-beam irradiation in clinical stage III non-small cell lung cancer: mature results of stereotactic body radiation therapy post radiation therapy (SBRTpostRT) study.
Article in La Radiologia medica, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 13 citations in OpenAlex.
- Definitive (chemo)radiotherapy of enteric-type adenocarcinoma of the lung: time to unmask an underrated treatment option?Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2025Article
- Expression of cancer stem cell markers and their prognostic significance in stage IIIA non-small cell lung cancer.World journal of stem cells · 2025Article
- Bulky non-small cell lung cancer treated with two-field robust proton lattice boost followed by conventional chemoradiation.Clinical and translational radiation oncology · 2025Article
- Stereotactic radiotherapy for oligometastatic mediastinal lymph-nodes: a multicentre retrospective experience.Clinical & experimental metastasis · 2025Article
- Design and Development of a Device (SifilottoCurrent oncology (Toronto, Ont.) · 2025Article
- Segmental bronchi radiation dose affected the progression of radiation pneumonitis in lung cancer patients.Discover oncology · 2025Article
- Article
- Evaluation of risk factors for difficult-to-control pain (VAS score > 3) at two months after late-stage non-small cell lung cancer treatment with iodine-125 radioactive particle implantation combined with chemotherapy.Journal of contemporary brachytherapy · 2025Article
- Interstitial High-Dose-Rate Brachytherapy Combined with External Beam Radiation Therapy for Dose Escalation in the Primary Treatment of Locally Advanced, Non-Resectable Superior Sulcus (Pancoast) Tumors: Results of a Monocentric Retrospective Study.Journal of clinical medicine · 2024Article
- Treatment for paraganglioma with stereotactic radiotherapy.World journal of clinical cases · 2024Article
- Gene expression signature predicts radiation sensitivity in cell lines using the integral of dose-response curve.BMC cancer · 2024Article
- A pH-Sensitive Nanoparticle as Reactive Oxygen Species Amplifier to Regulate Tumor Microenvironment and Potentiate Tumor Radiotherapy.International journal of nanomedicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the role of stereotactic body radiation therapy (SBRT) delivered after external-beam fractionated irradiation in non-small-cell lung cancer (NSCLC) patients with clinical stage III A, B. MATERIALS AND
methodsAll patients received three-dimensional conformal radiotherapy (3D-CRT) or intensity modulated radiation therapy (IMRT) (60-66 Gy/30-33 fractions of 2 Gy/5 days a week) with or without concomitant chemotherapy. Within 60 days from the end of irradiation, a SBRT boost (12-22 Gy in 1-3 fractions) was delivered on the residual disease.
resultsHere we report the mature results of 23 patients homogeneously treated and followed up for a median time of 5.35 years (range 4.16-10.16). The rate of overall clinical response after external beam and stereotactic boost was 100%. No treatment-related mortality was recorded. Radiation-related acute toxicities with a grade ≥ 2 were observed in 6/23 patients (26.1%): 4/23 (17.4%) had esophagitis with mild esophageal pain (G2); in 2/23 (8.7%) clinical radiation pneumonitis G2 was observed. Lung fibrosis (20/23 patients, 86.95%) represented a typical late tissue damage, which was symptomatic in one patient. Median disease-free survival (DFS) and overall survival (OS) were 27.8 (95% CI, 4.2-51.3) and 56.7 months (95% CI, 34.9-78.5), respectively. Median local progression-free survival (PFS) was 17 months (range 11.6-22.4), with a median distant PFS of 18 months (range 9.6-26.4). The 5-year actuarial DFS and OS rates were 28.7% and 35.2%, respectively.
conclusionsWe confirm that a stereotactic boost after radical irradiation is feasible in stage III NSCLC patients. All fit patients who have no indication to adjuvant immunotherapy and presenting residual disease after curative irradiation could benefit from stereotactic boost because outcomes seem to be better than might be historically assumed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.